End-of-day quote
Korea S.E.
06:00:00 2024-05-13 pm EDT
|
5-day change
|
1st Jan Change
|
3,970
KRW
|
-0.38%
|
|
-7.35%
|
-8.94%
|
Mar. 15 |
Meta Biomed Co., Ltd.'s Equity Buyback Plan Extended till March 16, 2026.
|
CI
| Mar. 11 |
Meta Biomed Co., Ltd. announced that it has received KRW 24 billion in funding from Mirae Asset Securities Co., Ltd., Samsung Securities Co., Ltd., KB Securities Co., Ltd., NH Investment & Securities Co., Ltd., Shinhan Investment & Securities Co., Ltd., KB-Suseong No. 1 New Technology Business Investment Association
|
CI
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
68,950
|
64,799
|
64,352
|
66,184
|
52,832
|
99,718
|
Enterprise Value (EV)
1 |
94,000
|
95,169
|
93,216
|
84,746
|
77,763
|
127,356
|
P/E ratio
|
-59.5
x
|
19.4
x
|
-15.8
x
|
6.95
x
|
20.1
x
|
9.89
x
|
Yield
|
0.34%
|
0.36%
|
0.36%
|
0.69%
|
0.87%
|
0.46%
|
Capitalization / Revenue
|
1.08
x
|
1.09
x
|
1.36
x
|
1.13
x
|
0.77
x
|
1.2
x
|
EV / Revenue
|
1.47
x
|
1.6
x
|
1.97
x
|
1.44
x
|
1.13
x
|
1.53
x
|
EV / EBITDA
|
-145
x
|
10.1
x
|
16.1
x
|
9.6
x
|
8.46
x
|
8.59
x
|
EV / FCF
|
-7.07
x
|
-22.8
x
|
65.6
x
|
15
x
|
-12.6
x
|
-38.2
x
|
FCF Yield
|
-14.1%
|
-4.39%
|
1.52%
|
6.67%
|
-7.96%
|
-2.62%
|
Price to Book
|
1.37
x
|
1.22
x
|
1.34
x
|
1.13
x
|
0.87
x
|
1.42
x
|
Nbr of stocks (in thousands)
|
23,492
|
23,267
|
22,901
|
22,901
|
22,871
|
22,871
|
Reference price
2 |
2,935
|
2,785
|
2,810
|
2,890
|
2,310
|
4,360
|
Announcement Date
|
3/20/19
|
3/18/20
|
3/17/21
|
3/18/22
|
3/21/23
|
3/21/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
1 |
63,813
|
59,391
|
47,209
|
58,780
|
68,942
|
83,101
|
EBITDA
1 |
-649
|
9,466
|
5,790
|
8,832
|
9,196
|
14,825
|
EBIT
1 |
-4,080
|
5,753
|
1,848
|
5,261
|
5,336
|
10,602
|
Operating Margin
|
-6.39%
|
9.69%
|
3.91%
|
8.95%
|
7.74%
|
12.76%
|
Earnings before Tax (EBT)
1 |
616.8
|
5,925
|
-4,619
|
7,584
|
3,988
|
7,805
|
Net income
1 |
-1,148
|
3,346
|
-4,093
|
9,522
|
2,628
|
10,080
|
Net margin
|
-1.8%
|
5.63%
|
-8.67%
|
16.2%
|
3.81%
|
12.13%
|
EPS
2 |
-49.30
|
143.4
|
-178.0
|
415.8
|
114.8
|
440.7
|
Free Cash Flow
1 |
-13,290
|
-4,182
|
1,420
|
5,650
|
-6,193
|
-3,338
|
FCF margin
|
-20.83%
|
-7.04%
|
3.01%
|
9.61%
|
-8.98%
|
-4.02%
|
FCF Conversion (EBITDA)
|
-
|
-
|
24.53%
|
63.97%
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
59.34%
|
-
|
-
|
Dividend per Share
2 |
10.00
|
10.00
|
10.00
|
20.00
|
20.00
|
20.00
|
Announcement Date
|
3/20/19
|
3/18/20
|
3/17/21
|
3/18/22
|
3/21/23
|
3/21/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
25,050
|
30,370
|
28,864
|
18,562
|
24,931
|
27,638
|
Net Cash position
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-38.59
x
|
3.208
x
|
4.986
x
|
2.102
x
|
2.711
x
|
1.864
x
|
Free Cash Flow
1 |
-13,290
|
-4,182
|
1,420
|
5,650
|
-6,193
|
-3,338
|
ROE (net income / shareholders' equity)
|
-2.25%
|
10.8%
|
-7.84%
|
17.4%
|
5.83%
|
14.7%
|
ROA (Net income/ Total Assets)
|
-2.35%
|
3.58%
|
1.09%
|
3.12%
|
2.97%
|
5.28%
|
Assets
1 |
48,929
|
93,528
|
-374,138
|
305,471
|
88,331
|
191,065
|
Book Value Per Share
2 |
2,142
|
2,289
|
2,095
|
2,547
|
2,649
|
3,063
|
Cash Flow per Share
2 |
235.0
|
101.0
|
377.0
|
442.0
|
578.0
|
472.0
|
Capex
1 |
9,081
|
7,561
|
2,227
|
2,067
|
15,395
|
11,489
|
Capex / Sales
|
14.23%
|
12.73%
|
4.72%
|
3.52%
|
22.33%
|
13.83%
|
Announcement Date
|
3/20/19
|
3/18/20
|
3/17/21
|
3/18/22
|
3/21/23
|
3/21/24
|
|